Press Releases BioLineRx Ltd.

Equities

BLRX

IL0011015182

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:13 2024-06-27 EDT			5-day change	1st Jan Change
15.3 ^ILa	-1.92%		-4.38%	-59.95%

05-30	BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease	CI
05-28	Transcript : BioLineRx Ltd., Q1 2024 Earnings Call, May 28, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapy Applications in Sickle Cell Disease	05-31	AQ
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	05-29	AQ
BioLineRx : Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates	05-28	PU
BioLineRx to Report First Quarter 2024 Results on May 28, 2024	05-22	PR
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification	05-20	AQ
BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024	05-06	PU
BioLineRx : Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	04-17	PU
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	04-10	PR
BioLineRx Announces $6 Million Registered Direct Offering	04-02	AQ
BioLineRx : Form 20-F/A (Amendment No. 1	03-28	PU
BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	03-27	AQ
BioLineRx : Annual Report on Form 20-F FOR 2023	03-26	PU
BioLineRx : Report of Periodic or Interim Report	03-26	PU
BioLineRx : Reports 2023 Financial Results and Recent Corporate and Portfolio Updates	03-26	PU
BioLineRx to Report 2023 Annual Financial Results on March 26, 2024	03-20	PR
BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production	03-04	PR
BioLineRx : FORM F-3-REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933	12-31	PU
BioLineRx : FORM S-8-registration of Ordinary Shares to be issued under the Plan	12-31	PU
BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease	12-21	PR
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates	11-21	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BioLineRx Ltd.

Equities

BLRX

IL0011015182

Press Releases

Filters